Fakeeh Care inks MoU with Fosun Pharma to develop cell, gene therapies

08:36 AM (Mecca time) Argaam
Logo ofDr. Soliman Abdel Kader Fakeeh Hospital Co. (Fakeeh Care)

Logo of Dr. Soliman Abdel Kader Fakeeh Hospital Co. (Fakeeh Care)

Dr. Soliman Abdel Kader Fakeeh Hospital Co. (Fakeeh Care) and its subsidiaries signed a strategic memorandum of understanding (MoU) with Shanghai Fosun Pharmaceutical Co. Ltd. to bring advanced cell and gene therapies—most notably CAR-T—as well as AI-powered digital pathology and remote diagnostics to Saudi Arabia.

 

For more news on listed companies

 

The MoU was signed on April 27 and is valid for one year, the company said in a statement to Tadawul.

 

Aligned with Saudi Vision 2030, the partnership seeks to accelerate local development and delivery of cutting-edge treatments, enhance diagnostic accuracy, and establish Saudi Arabia as a regional hub for healthcare innovation, Fakeeh Care explained.

 

Advanced cell and gene therapy solutions, as well as AI-powered digital pathology and remote diagnostic services, will be introduced to Saudi Arabia, the company added.

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.